Please ensure Javascript is enabled for purposes of website accessibility

Why BioCryst Pharmaceuticals Stock Is Falling Today

By Prosper Junior Bakiny - Feb 25, 2021 at 2:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company's fourth-quarter earnings report did not pass muster.

What happened?

BioCryst Pharmaceuticals (BCRX -3.71%) stock is dropping sharply on Thursday after the biotech company reported disappointing fourth-quarter financial results. BioCryst's shares were down by 8.4% as of 1:53 p.m. EST. 

So what

BioCryst's total revenue for the fourth quarter ending Dec. 31 was roughly $4 million, down from the $39.7 million in revenue recorded during the year-ago period. In the fourth quarter of 2019, the company recognized a one-time revenue of $20.1 million, and it also reported $13.9 million in revenue from the sale of flu medicine Rapivab under a contract with the U.S. Department of Health and Human Services. During Q4 2020, BioCryst did not record any sales from Rapivab; these factors help explain the year-over-year decrease in the company's top line. 

Down-trending arrows on a blackboard

Image source: Getty Images.

Still, the biotech's revenue came in well short of the $14.74 million consensus analyst estimate. On the bottom line, BioCryst recorded a net loss of $60.5 million and a net loss per share of $0.34. During Q4 2019, the company reported a net loss of $2.6 million -- or $0.02 on a per-share basis. The consensus estimate for the company's bottom line was a net loss of $0.25. For the full fiscal year 2020, BioCryst posted total revenue of $17.8 million and a net loss per share of $1.09. Those metrics were below the $28.2 million in revenue and the $1 loss per share analysts expected.

Now what

Despite BioCryst's disappointing fourth-quarter financial results, investors have something to look forward to with this healthcare stock. Back in December, the U.S. Food and Drug Administration approved the company's Orladeyo, a once-daily pill to prevent hereditary angioedema attacks. The company expects this medicine to rack up global peak sales of more than half a million dollars. Thanks to Orladeyo, BioCryst's financial results could look much better this year than they did last year. 

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

BioCryst Pharmaceuticals, Inc. Stock Quote
BioCryst Pharmaceuticals, Inc.
$8.57 (-3.71%) $0.33

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/24/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.